טוען...
New options for the anemia of chronic kidney disease
Anemia is a common complication of chronic kidney disease. Use of erythropoiesis-stimulating agents (ESA) has been a mainstay of treatment since 1990. A series of large trials demonstrated that ESAs have serious safety problems, including increasing cardiovascular and thrombotic events, and death. A...
שמור ב:
| הוצא לאור ב: | Kidney Int Suppl (2011) |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6341017/ https://ncbi.nlm.nih.gov/pubmed/30675430 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.kisu.2017.09.002 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|